AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9590461 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg compressed tablet (CT)
Number of subjects: 6
Study 9590461 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg sustained release (SR) tablet
Number of subjects: 6
Study 9590461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8145983 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF)
Number of subjects: 2
Study 8145983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2
Study 3197978 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with one dose of 90 g corn oil after the last meal (120 g fat/day)
Number of subjects: 30
Study 3197978 — intervention group
Group type: COMPARATOR
Intervention: Basal low fat diet containing 30 g of fat per day
Number of subjects: 30
Study 3197978 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with doses of 30 g corn oil taken with each of the three meals (120 g fat/day)
Number of subjects: 30
Study 30642738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral citrulline supplementation (0.18 g/kg/day)
Number of subjects: 9
Study 30642738 — intervention group
Group type: COMPARATOR
Intervention: Iso-nitrogenous placebo
Number of subjects: 9
Study 30642738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral citrulline supplementation
Number of subjects: 9
Study 28600758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 113
Study 28600758 — intervention group
Group type: COMPARATOR
Intervention: Prolapse surgery
Number of subjects: 113
Study 27524680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine titration
Number of subjects: 293
Study 27524680 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 293
Study 24295507 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 136
Study 24295507 — intervention group
Group type: COMPARATOR
Intervention: Attention control task
Number of subjects: 136
Study 22525372 — intervention group
Group type: EXPERIMENTAL
Intervention: Houttuyninum (5.52 μg/ml IC50)
Number of subjects: 0
Study 22525372 — intervention group
Group type: EXPERIMENTAL
Intervention: Houttuyninum (in vivo administration)
Number of subjects: 0
Study 22525372 — intervention group
Group type: EXPERIMENTAL
Intervention: Houttuyninum (40 μg/ml)
Number of subjects: 0
Study 22525372 — intervention group
Group type: EXPERIMENTAL
Intervention: Houttuyninum
Number of subjects: 0
Study 19460169 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy directed to the talocrural joint
Number of subjects: 0
Study 19460169 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 17529847 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d orally)
Number of subjects: 50
Study 17529847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16002037 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention with family activities (N=29)
Number of subjects: 159
Study 16002037 — intervention group
Group type: COMPARATOR
Intervention: No family activities (N=130)
Number of subjects: 159
Study 15832486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 265
Study 15832486 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 265
Study 10435732 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA-IgG
Number of subjects: 13
Study 10435732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7624915 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐SIM (300 mg single dose)
Number of subjects: 16
Study 7624915 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐SIM
Number of subjects: 16
Study 2190516 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg, four times daily for 3 weeks
Number of subjects: 77
Study 2190516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2190516 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 77
Study 38695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg
Number of subjects: 0
Study 38695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.010 to 0.020 mg/kg
Number of subjects: 0
Study 30672793 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Mesh Excision (PME)
Number of subjects: 1904
Study 30672793 — intervention group
Group type: COMPARATOR
Intervention: Complete Mesh Excision (CME)
Number of subjects: 1904
Study 30455090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 28526394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=11,483)
Number of subjects: 58505
Study 28526394 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=47,122)
Number of subjects: 58505
Study 25926146 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red blood cell (RBC) transfusion thresholds
Number of subjects: 936
Study 25926146 — intervention group
Group type: COMPARATOR
Intervention: Liberal red blood cell (RBC) transfusion thresholds
Number of subjects: 936
Study 25926146 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge healthcare costs
Number of subjects: 936
Study 25926146 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 936
Study 25926146 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual initial in-hospital treatment cost for all AUGIB cases in the UK
Number of subjects: 936
Study 25926146 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental costs of treating hospitalised patients developing AUGIB
Number of subjects: 936
Study 23340242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Fat Quality Assessment (DFQA)
Number of subjects: 120
Study 23340242 — intervention group
Group type: COMPARATOR
Intervention: Food frequency questionnaire
Number of subjects: 120
Study 21407248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) for 3 months and dietary counselling at discharge
Number of subjects: 114
Study 21407248 — intervention group
Group type: COMPARATOR
Intervention: Only dietary counselling at discharge (Control)
Number of subjects: 114
Study 21407248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 114
Study 18787937 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction of over-selected stimuli
Number of subjects: 0
Study 18787937 — intervention group
Group type: COMPARATOR
Intervention: Behavioral control by previously over-selected stimulus extinguished
Number of subjects: 0
Study 17353582 — intervention group
Group type: EXPERIMENTAL
Intervention: Neptune Krill Oil (NKO) 300 mg daily
Number of subjects: 90
Study 17353582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15492322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 1439
Study 15492322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 1439
Study 15492322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1439
Study 11951578 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramide (N) administered intramuscularly twice daily for 28 days
Number of subjects: 92
Study 11951578 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramide (N)
Number of subjects: 92
Study 11951578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 92
Study 11951578 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramide (N) and Placebo (P)
Number of subjects: 92
Study 9517372 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (10 to 30 microg min(‐1))
Number of subjects: 6
Study 8039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (30 patients) operated on without preoperative [18F]FDG/PET
Number of subjects: 74
Study 8039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (37 patients) operated on with FDG uptake in segments with wall motion abnormalities
Number of subjects: 74
Study 8039194 — intervention group
Group type: COMPARATOR
Intervention: Group C (7 patients) with no FDG uptake, who were excluded from coronary surgery
Number of subjects: 74
Study 3377230 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal warming (warm room, humidified respiratory gases, and warm intravenous fluids)
Number of subjects: 10
Study 3377230 — intervention group
Group type: COMPARATOR
Intervention: Standard temperature management (no special warming measures)
Number of subjects: 10
Study 31167512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot polyphenol extract complex (BPE‐C) 650 mg daily
Number of subjects: 52
Study 31167512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot polyphenol extract complex (BPE‐C) 1300 mg daily
Number of subjects: 52
Study 31167512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 27846629 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloon (DEB) after Cutting Balloon (CB) dilation
Number of subjects: 120
Study 27846629 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES) implantation alone
Number of subjects: 120
Study 25791668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) - medical therapy plus psychotherapy (8 group and 2 individual sessions)
Number of subjects: 158
Study 25791668 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) - medical therapy alone
Number of subjects: 158
Study 25791668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) - medical therapy plus psychotherapy
Number of subjects: 158
Study 23571784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (2 × 250 ml for 3 days postoperatively)
Number of subjects: 334
Study 23571784 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 0.9% (control group)
Number of subjects: 334
Study 23571784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6%
Number of subjects: 334
Study 23571784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% and Saline solution 0.9%
Number of subjects: 334
Study 21963127 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (15, 30 or 60μg/kg daily)
Number of subjects: 406
Study 21963127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 19819787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily
Number of subjects: 38
Study 19819787 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50 mg daily
Number of subjects: 38
Study 16706303 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating with RZ (RZII)
Number of subjects: 36
Study 16706303 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating with SE/PLF (Clearfil SE Bond and Protect Liner F)
Number of subjects: 36
Study 16706303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no resin coating)
Number of subjects: 36
Study 15051198 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 500
Study 15051198 — intervention group
Group type: COMPARATOR
Intervention: ECCE
Number of subjects: 500
Study 11709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 16
Study 11709433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11709433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 9670411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 7719087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (laparoscopy + TCM including low dose Methotrexate, modified Huo‐Luo‐Xiao‐Ling Dan, Ding‐Tong paste, Zi‐Gong pill)
Number of subjects: 44
Study 7719087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 44
Study 7719087 — intervention group
Group type: COMPARATOR
Intervention: Control group (using TCM only)
Number of subjects: 44
Study 2563046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1846
Study 2563046 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1846
Study 4832320 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper 7 IUCD
Number of subjects: 121
Study 4832320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon shield IUCD
Number of subjects: 121
Study 31056272 — intervention group
Group type: EXPERIMENTAL
Intervention: Supercritical fluid chromatography (SFC) method for quantifying flupirtine and its metabolites (4‐fluorohippuric acid and D‐13223)
Number of subjects: 0
Study 31056272 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC method applied to clinical samples after single intravenous (100 mg), single oral (100 mg), and repeated oral administration (400 mg)
Number of subjects: 0
Study 27922025 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 3303
Study 27922025 — intervention group
Group type: COMPARATOR
Intervention: Traditional Air Insufflation (AI)
Number of subjects: 3303
Study 26366072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele monitoring (TM) with video consultations
Number of subjects: 281
Study 26366072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 281
Study 24024587 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM training for general practitioners (GPs)
Number of subjects: 1120
Study 24024587 — intervention group
Group type: COMPARATOR
Intervention: Usual care without prior SDM training for GPs
Number of subjects: 1120
Study 22462236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 10
Study 22462236 — intervention group
Group type: COMPARATOR
Intervention: Breast milk only (Control)
Number of subjects: 10
Study 19346975 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Armor (MA) supplementation
Number of subjects: 17
Study 19346975 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous placebo (CON)
Number of subjects: 17
Study 16762702 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg preoperatively, 200 mg postoperatively)
Number of subjects: 200
Study 16762702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16762702 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 200
Study 15589355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight deep breaths (8DB)
Number of subjects: 20
Study 15589355 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume breathing (3TV)
Number of subjects: 20
Study 15328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg at 21:30, followed by 100 mg at 03:00 and 05:00)
Number of subjects: 16
Study 15328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16
Study 15328782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10718163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 125 mg
Number of subjects: 8
Study 10718163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 250 mg
Number of subjects: 8
Study 10718163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8883530 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol at 320 mg I/kg
Number of subjects: 46
Study 8883530 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 46
Study 1547766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal diazepam (DZP) 20 mg
Number of subjects: 39
Study 1547766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal diazepam (DZP) 30 mg
Number of subjects: 39
Study 1547766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal diazepam (DZP)
Number of subjects: 39
Study 2863922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg fluphenazine and 10 mg nortriptyline (Motival)
Number of subjects: 233
Study 2863922 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg fluphenazine
Number of subjects: 233
Study 2863922 — intervention group
Group type: COMPARATOR
Intervention: 10 mg nortriptyline
Number of subjects: 233
Study 2863922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 3341247 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement
Number of subjects: 30
Study 3341247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30051188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks with varying social and motor engagement
Number of subjects: 0
Study 30051188 — intervention group
Group type: EXPERIMENTAL
Intervention: Social engagement
Number of subjects: 0
Study 30051188 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 0
Study 31593070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High Flow (NHF) therapy
Number of subjects: 400
Study 31593070 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COT)
Number of subjects: 400
Study 28917545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg three times a day)
Number of subjects: 6522
Study 26350812 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/d
Number of subjects: 41
Study 26350812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23083494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated abdominal belt to optimal therapeutic pressures
Number of subjects: 80
Study 23083494 — intervention group
Group type: COMPARATOR
Intervention: Minimal, non-therapeutic pressures abdominal belt
Number of subjects: 80
Study 21839402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (45 mg at Weeks 0 and 4)
Number of subjects: 0
Study 21839402 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg biweekly)
Number of subjects: 0
Study 21839402 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab vs Etanercept
Number of subjects: 0
Study 19847865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 60
Study 19847865 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 16737665 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador Quercus (IQ)
Number of subjects: 43
Study 16737665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe lectin (ML) derived from IQ
Number of subjects: 43
Study 16737665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16737665 — intervention group
Group type: COMPARATOR
Intervention: IQ depleted of ML
Number of subjects: 43
Study 15649878 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated reduced gravity (reduced body weight)
Number of subjects: 0
Study 15649878 — intervention group
Group type: EXPERIMENTAL
Intervention: Added weight and mass
Number of subjects: 0
Study 15649878 — intervention group
Group type: EXPERIMENTAL
Intervention: Added mass alone (simulated reduced gravity + added load)
Number of subjects: 0
Study 15649878 — intervention group
Group type: EXPERIMENTAL
Intervention: Force to support body weight
Number of subjects: 0
Study 11680559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus group drug counseling
Number of subjects: 487
Study 11680559 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy plus group drug counseling
Number of subjects: 487
Study 11680559 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling plus group drug counseling
Number of subjects: 487
Study 11680559 — intervention group
Group type: COMPARATOR
Intervention: Group drug counseling alone
Number of subjects: 487
Study 9770877 — intervention group
Group type: EXPERIMENTAL
Intervention: Coccinia indica, 500 mg/kg body weight, administered orally for six weeks
Number of subjects: 30
Study 7819650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus preparation
Number of subjects: 62
Study 7819650 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 62
Study 7819650 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic tube feeding
Number of subjects: 62
Study 7819650 — intervention group
Group type: COMPARATOR
Intervention: Tube feeding
Number of subjects: 62
Study 3043355 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg bd)
Number of subjects: 305
Study 3043355 — intervention group
Group type: COMPARATOR
Intervention: doxycycline (200 mg once daily)
Number of subjects: 305
Study 31609637 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI plus panitumumab
Number of subjects: 96
Study 31609637 — intervention group
Group type: COMPARATOR
Intervention: FOLFOXIRI
Number of subjects: 96
Study 28456387 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 44
Study 28456387 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study 26385025 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time cardiovascular prevention consult
Number of subjects: 400
Study 26385025 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time cardiovascular prevention consult plus behavioral intervention program (telephone-based motivational interviewing and tailored text messages)
Number of subjects: 400
Study 26385025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 23696599 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 192
Study 23696599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remote ischemic preconditioning)
Number of subjects: 192
Study 21446609 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored breast cancer screening intervention delivered in church settings
Number of subjects: 0
Study 18849052 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding during immunization (for infants under 6 months)
Number of subjects: 243
Study 18849052 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sucrose solution (for children aged 6 to 48 months)
Number of subjects: 243
Study 18849052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (for children aged 6 to 48 months)
Number of subjects: 243